Fate Therapeutics, Inc. (FATE) Financials

FATE Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 284.9 million 105.2 million
Dec. 31, 2025 318.9 million 111.8 million
Sept. 30, 2025 343.7 million 109.6 million
June 30, 2025 371.6 million 110.3 million

FATE Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -31.1 million 3.9 million
Dec. 31, 2025 -24.5 million 5.5 million
Sept. 30, 2025 -26.6 million 4.9 million
June 30, 2025 -25.9 million 7.2 million

FATE Net Income

No data available :(

FATE Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 174.8 million 72.0 million 76.8 million
Dec. 31, 2025 203.7 million 73.3 million 77.8 million
Sept. 30, 2025 215.4 million - 79.2 million
June 30, 2025 222.8 million - 81.3 million

FATE Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 120.0 million
Dec. 31, 2025 118.8 million
Sept. 30, 2025 119.0 million
June 30, 2025 118.5 million

FATE Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 239000 21.8 million 9.6 million -
Dec. 31, 2025 1.2 million 25.4 million 10.7 million -
Sept. 30, 2025 2.2 million 25.8 million 10.6 million -
June 30, 2025 1.4 million 27.4 million 11.4 million -

FATE Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 1.3 million 2.9 million
Dec. 31, 2025 1.4 million 3.1 million
Sept. 30, 2025 1.7 million -
June 30, 2025 1.9 million 3.3 million

FATE Revenue by Segment
Graph available only for paid members. Upgrade to see it.

FATE

Price: $2.41

52 week price:
0.91
3.21

Earnings Per Share: -1.09 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 1.6 million

Ebitda: -10.1 million

Market Capitalization: 340.4 million

Links: